Bionomics Limited participated in the H.C Wainwright BioConnect Conference
Bionomics Limited (NASDAQ:BNOX) participated in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. Dr. Errol De Souza, Executive Chairman, highlighted BNC210, a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor. The drug is in development for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. BNC210 has received Fast Track designation from the FDA for both conditions, marking a significant step in its clinical journey.
- BNC210 has FDA Fast Track designation for Social Anxiety Disorder and Post-Traumatic Stress Disorder.
- Participation in the H.C. Wainwright BioConnect Conference enhances visibility among investors.
- None.
ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.
Dr Errol De Souza, Executive Chairman of Bionomics, provided an update on the Company including BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD), with U.S. Food and Drug Administration (FDA) Fast Track designation for both clinical indications.
The presentation is available on the Company's website https://www.bionomics.com.au/investor-centre/presentations-posters/
FOR FURTHER INFORMATION PLEASE CONTACT:
General: | Investor Relations: |
Ms Suzanne Irwin | Mr. Connor Bernstein |
Company Secretary | Vice President, Strategy and Corporate Development |
+61 8 8150 7400 | +1 (831) 246-3642 |
About Bionomics Limited
Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
View original content:https://www.prnewswire.com/news-releases/bionomics-limited-participated-in-the-hc-wainwright-bioconnect-conference-301459281.html
SOURCE Bionomics Limited
FAQ
What is Bionomics Limited's focus area?
What are the clinical trials involving BNC210?
What recent event did Bionomics Limited participate in?
What is the significance of the FDA Fast Track designation for BNC210?
